You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

high-risk biochemically-recurrent

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostate Cancer Trial in Boston, South Weymouth, Londonderry (Nivolumab)

Recruiting
  • Prostate Cancer
  • Boston, Massachusetts
  • +4 more
Dec 5, 2022

Prostate Trial in United States (Olaparib)

Recruiting
  • Prostate
  • Baltimore, Maryland
  • +3 more
Feb 14, 2022

Prostate Cancer Trial in Edmonton (18F-PSMA-1007)

Active, not recruiting
  • Prostate Cancer
  • 18F-PSMA-1007
  • Edmonton, Alberta, Canada
    University of Alberta
Aug 10, 2022

Prostate Cancer Trial in Pittsburgh (18F-DCFPyL)

Active, not recruiting
  • Prostate Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Mar 8, 2022

Circulating Tumor Cells in High Risk and Early Metastatic

Recruiting
  • High Risk Prostate Carcinoma
  • +3 more
  • Blood collection
  • Bala-Cynwyd, Pennsylvania
  • +1 more
Jun 28, 2022

Prostate Cancer Trial in Irvine (DCFPyL PET/CT)

Recruiting
  • Prostate Cancer
  • DCFPyL PET/CT
  • Irvine, California
    Hoag Memorial Hospital Presbyterian
Jul 26, 2021

Prostate Cancer Trial ([18F]-PSMA-1007)

Not yet recruiting
  • Prostate Cancer
  • [18F]-PSMA-1007
  • (no location specified)
Jan 30, 2023

Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (biological, drug, other)

Recruiting
  • Biochemically Recurrent Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Durvalumab
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Prostate Tumors, Prostatic Cancer, Prostate Cancer Trial run by the National Cancer Institute (NCI) (18F-DCFPyL, 18F-FDG,

Enrolling by invitation
  • Prostate Neoplasms
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma Trial in Beijing (multi-kinase inhibitors in

Not yet recruiting
  • Liver Transplant; Complications
  • +3 more
  • multi-kinase inhibitors in combination with bevacizumab
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Sep 11, 2023

LYNPARZA Breast Cancer in Adjuvant Setting Japan Post-Marketing

Not yet recruiting
  • Breast Cancer
    • (no location specified)
    Jan 9, 2023

    Barrett Oesophagitis With Dysplasia Trial in Kansas City (Itraconazole in capsule form, Itraconazole in solution form)

    Recruiting
    • Barrett Oesophagitis With Dysplasia
    • Itraconazole in capsule form
    • Itraconazole in solution form
    • Kansas City, Kansas
      University of Kansas Medical Center
    Nov 1, 2022

    Colorectal Liver Metastasis Trial in Shanghai (HAIC-FOLFOX combined with Sintilimab and Regorafenib)

    Recruiting
    • Colorectal Liver Metastasis
    • HAIC-FOLFOX combined with Sintilimab and Regorafenib
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Mar 1, 2023

    Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Stage I Skin Cancer Trial in Los Angeles,

    Recruiting
    • Recurrent Skin Squamous Cell Carcinoma
    • +4 more
    • Cemiplimab
    • Resection
    • Los Angeles, California
    • +2 more
    Nov 12, 2022

    Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome Trial in

    Recruiting
    • Acute Myeloid Leukemia
    • +7 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 7, 2022

    Neuroblastoma Trial in Cologne (antibody ch14.18, GM-CSF, IL-2 i.v.)

    Terminated
    • Neuroblastoma
    • antibody ch14.18
    • +4 more
    • Cologne, Germany
      University of Cologne
    Nov 3, 2022

    Diabetes, Peripheral Neuropathy, Diabetic Foot Trial (Orpyx SI Sensory Insole System)

    Not yet recruiting
    • Diabetes
    • +3 more
    • Orpyx SI Sensory Insole System
    • (no location specified)
    Jul 11, 2023

    High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston

    Completed
    • High Risk Myelodysplastic Syndrome
    • +2 more
    • Daratumumab
    • Houston, Texas
      M D Anderson Cancer Center
    Nov 21, 2022

    Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,

    Active, not recruiting
    • Adult Grade III Lymphomatoid Granulomatosis
    • +23 more
    • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
    • +2 more
    • Duarte, California
      City of Hope Medical Center
    Jan 4, 2023

    Recurrent Neuroblastoma Trial in Germany (metronomic therapy)

    Recruiting
    • Recurrent Neuroblastoma
    • metronomic therapy
    • Bonn, Germany
    • +7 more
    Nov 3, 2022

    High Risk Prostate Carcinoma Trial in Gyeonggi-do, Seoul, Soeul ([F-18]Florastamin)

    Recruiting
    • High Risk Prostate Carcinoma
    • Gyeonggi-do, Korea, Republic of
    • +5 more
    Jun 29, 2023

    Prostate Cancer Trial in United States (Apalutamide, LHRH Analogue, Abiraterone Acetate)

    Active, not recruiting
    • Prostate Cancer
    • Phoenix, Arizona
    • +68 more
    Nov 28, 2022

    Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 Trial in

    Recruiting
    • Biochemically Recurrent Prostate Carcinoma
    • +4 more
    • Educational Intervention
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 13, 2021

    Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine,

    Active, not recruiting
    • Acute Myeloid Leukemia
    • +5 more
    • Duarte, California
      City of Hope Medical Center
    Jan 4, 2023

    Head and Neck Tumors Trial in Detroit (Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA])

    Recruiting
    • Head and Neck Neoplasms
    • Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
    • Detroit, Michigan
      Henry Ford Health System
    Dec 19, 2022